PHASE-II STUDY OF DOCETAXEL (TAXOTERE) IN PATIENTS WITH PREVIOUSLY UNTREATED EXTENSIVE SMALL-CELL LUNG-CANCER - A TRIAL OF THE NATIONAL-CANCER-INSTITUTE OF CANADA CLINICAL-TRIALS GROUP (NCIC CTG)

Authors
LATREILLE J CORMIER Y MARTINS H GOSS G FISHER B EISENHAUER EA
Citation
J. Latreille et al., PHASE-II STUDY OF DOCETAXEL (TAXOTERE) IN PATIENTS WITH PREVIOUSLY UNTREATED EXTENSIVE SMALL-CELL LUNG-CANCER - A TRIAL OF THE NATIONAL-CANCER-INSTITUTE OF CANADA CLINICAL-TRIALS GROUP (NCIC CTG), Investigational new drugs, 13(4), 1995, pp. 343-345
Citations number
4
Categorie Soggetti
Pharmacology & Pharmacy",Oncology
Journal title
Investigational new drugs → ACNP
ISSN journal
01676997
Volume
13
Issue
4
Year of publication
1995
Pages
343 - 345
Database
ISI
SICI code
0167-6997(1995)13:4<343:PSOD(I>2.0.ZU;2-2
Abstract
The objective of this multicenter phase II study was to evaluate the a ctivity of docetaxel in previously untreated small cell lung cancer. F ourteen patients were treated at a dose of 75 mg/m(2) intravenously ev ery three weeks. Of the 12 patients evaluable for response, one had a partial response for a duration of 12 weeks for a response rate of 8.3 %. Toxicity was mild. We conclude that docetaxel has, at the dose give n in this study, little activity in previously untreated small cell lu ng cancer.